论文部分内容阅读
目的研究liguzinediol在大鼠体内的药动学特征及其绝对生物利用度。方法 36只SD大鼠,♀♂各半,灌胃或尾静脉给予不同剂量liguzinediol,于不同时间点分取血浆,采用UPLC方法对血浆中liguzinediol的浓度进行测定,运用DAS 2.0药动学软件计算药动学参数及绝对生物利用度。结果灌胃给予liguzinediol高、中、低剂量(50、20、10 mg·kg~(-1))与静脉给予liguzinediol高、中、低剂量(20、10、5 mg·kg~(-1))的AUC_(0-∞)和给药剂量呈线性关系,在大鼠体内的口服绝对生物利用度大于90%。结论 Liguzinediol符合线性药动学,口服绝对生物利用度高,半衰期较短。
Objective To study the pharmacokinetics and bioavailability of liguzinediol in rats. Methods Thirty-six Sprague-Dawley rats were randomly divided into three groups: guinea pigs injected with different doses of liguzinediol by intragastric or caudal vein at different time points, plasma concentrations of liguzinediol were determined by UPLC method and calculated by DAS 2.0 pharmacokinetic software Pharmacokinetic parameters and absolute bioavailability. Results High, medium and low doses of liguzinediol (50, 20 and 10 mg · kg -1) were administered intragastrically to rats in high, medium and low doses of liguzinediol (20, 10, and 5 mg · kg -1) ) Had a linear relationship with the dose of AUC 0-∞, and its absolute oral bioavailability in rats was more than 90%. Conclusions Liguzinediol is in accordance with the linear pharmacokinetics and has high absolute oral bioavailability and short half-life.